Under the research collaboration and licensing agreement, the companies will work on the worldwide development and commercialisation of DCR-HBVS, Dicerna’s investigational therapy in phase 1 clinical development for
Validation confirms that the submission is complete and signifies the MAA is under review by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The U.S. Food
Under the deal, Cheplapharm will acquire the commercial rights of Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release). The compound patent protection for Seroquel
The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platform, Femtogenix has developed a lower potency DNA mono-alkylator
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, which is associated
Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases,
AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. The Company is actively recruiting
The FDA has approved Opdivo flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused over 60 minutes every four
This pivotal trial will evaluate the safety and efficacy of a single dose of FCR001, the company’s investigational cell therapy designed to durably free LDKT recipients from immunosuppression
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.